Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more
Combigene AB (COMBI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.087x
Based on the latest financial reports, Combigene AB (COMBI) has a cash flow conversion efficiency ratio of -0.087x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.23 Million) by net assets (Skr71.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Combigene AB - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Combigene AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Combigene AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Combigene AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aferian Plc
PINK:AOECF
|
-0.083x |
|
Secos Group Ltd
AU:SES
|
-0.064x |
|
PLYTEC Holding Berhad
KLSE:0289
|
0.064x |
|
Boutique Corporation Public Company Limited
BK:BC
|
0.049x |
|
Kesla Oyj A
HE:KELAS
|
0.068x |
|
GPO Plus Inc
OTCQB:GPOX
|
0.045x |
|
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk PT
JK:JMAS
|
-0.165x |
|
Africa Energy Corp
PINK:HPMCF
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Combigene AB (2012–2024)
The table below shows the annual cash flow conversion efficiency of Combigene AB from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr71.58 Million | Skr-29.95 Million | -0.418x | -59.46% |
| 2023-12-31 | Skr116.46 Million | Skr-30.56 Million | -0.262x | -139.51% |
| 2022-12-31 | Skr152.12 Million | Skr-16.67 Million | -0.110x | -178.41% |
| 2021-12-31 | Skr158.28 Million | Skr22.11 Million | 0.140x | +126.03% |
| 2020-12-31 | Skr71.43 Million | Skr-38.35 Million | -0.537x | +49.55% |
| 2019-12-31 | Skr20.30 Million | Skr-21.60 Million | -1.064x | -9662.78% |
| 2018-12-31 | Skr20.46 Million | Skr227.60K | 0.011x | +100.76% |
| 2017-12-31 | Skr6.51 Million | Skr-9.53 Million | -1.463x | +32.24% |
| 2016-12-31 | Skr4.08 Million | Skr-8.81 Million | -2.159x | -252.65% |
| 2015-12-31 | Skr10.27 Million | Skr-6.29 Million | -0.612x | -458.89% |
| 2014-12-31 | Skr5.67 Million | Skr-620.67K | -0.110x | +75.90% |
| 2013-12-31 | Skr598.60K | Skr-272.15K | -0.455x | -328.90% |
| 2012-12-31 | Skr298.09K | Skr59.21K | 0.199x | -- |